DBV Technologies stock rebounds by over 4%, 2nd in the SBF 120
The Châtillon biotech company posts a strong rebound at the end of Thursday, September 17, standing out in a moderately rising SBF 120. The movement comes as the Fed has just raised its key rates for the first time since 2023, in a macro context that nonetheless pushes many stocks toward caution.
A marked rebound that does not yet offset the quarterly decline of 26%
DBV Technologies gains 4.2% during the session, at €2.18, versus €2.10 at the previous close. The stock thus rises to 2nd place in the SBF 120, among the strongest gainers in the index, in a Paris market advancing approximately 0.6% as the close approaches. This rebound eases recent pressure without erasing it: over one month, the stock still loses 7.69%, and over three months the decline reaches 26.07%, reflecting the turbulence experienced since summer.
Over one year, by contrast, performance stands at +34%, a sign that the underlying momentum remains favorable despite recent setbacks. Volatility remains elevated at 20.31% over one month, which is consistent with the profile of a biotech in advanced regulatory phase. When publishing first-half 2026 results (July 16, 2026), the company indicated it anticipated submitting its BLA to the FDA in the third quarter of 2026, with cash reserves covering needs through the third quarter of 2027.
A fragile technical configuration despite today's rebound, with rising bearish positions
Technically, the stock remains under structural pressure. It trades below its 20-day MA (€2.34, a difference of -6.67%) and its 50-day MA (€2.45, a difference of -10.86%), two levels that both constitute resistance to overcome to confirm a reversal. The RSI at 33 approaches oversold territory without entering it, reflecting the selling exhaustion of recent weeks while leaving the door open for a more sustained rebound. The €2.07 support is holding for now, while the €2.57 resistance represents the first target to monitor.
Furthermore, according to recorded disclosures, three funds cumulatively held 3.70% of capital sold short as of September 11, up nearly one percentage point over thirty days. This level, above the 3% threshold, signals a significant institutional presence positioned against the stock, whose recent increase deserves to be monitored without drawing definitive conclusions about the security's direction. The analyst consensus on DBV Technologies remains the fundamental benchmark for assessing revaluation potential relative to the current price.
